Page 20 - Haematologica Vol. 109 - July 2024

EDITORIAL
E. Bachy
been selected (or omitted), and the reason why they have been incorporated or not, should be thoroughly examined. Third, inclusion/exclusion criteria, outcome definition, balance in the average baseline character- istics after matching and sensitivity analyses should be key in interpreting results of MAIC. Finally, extreme caution should always be applied when drawing con- clusions based on such indirect comparisons and one should remember that only well-controlled randomized study can balance unmeasured confounders. Regarding
References
1. Maurer MJ, Casulo C, Larson MC, et al. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024;109(7):2177-2185.
2. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065.
3. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935-945.
4. Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative
all these critical points, this academy-concepted study will be highly informative to the reader beyond results of the comparison itself and despite all limitations of the statistical approach.
Disclosures
Honorarium/Ad Board from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer, Incyte, ADC Therapeutics, Roche, Takeda; fees from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer; funding from Amgen, BMS.
effectiveness research. Value Health. 2012;15(6):940-947.
5. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of
high-risk subgroups. Blood Cancer J. 2020;10(7):74.
6. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in
follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144-152.
7. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
8. Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096-1101.
Haematologica | 109 July 2024
2034